Physician profile
Memory Gunsaru
NPI 1891081303
$5,093.36
in general payments reported to CMS, 2019-2025
36 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,286 · 2024: $1,984 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.40 | 2023-2025 | |
| Novo Nordisk INC | $692.51 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $602.29 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $397.62 | 2023-2025 | Zepbound, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $271.90 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $221.67 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $194.77 | 2023-2025 | Rexulti |
| Verona Pharma, INC. | $158.12 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $151.59 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.83 | 2023-2025 | Xifaxan |
| Amgen INC. | $150.13 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $149.26 | 2023-2025 | |
| Axsome Therapeutics, INC. | $134.74 | 2023-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.20 | 2023-2025 | Jardiance |
| Dexcom, INC. | $98.59 | 2023-2025 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Memory Gunsaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.